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Treatment of refractory Wegener’s granulomatosis with antithy-
mocyte globulin (ATG): An open study in 15 patients.
Background. A subset of patients with Wegener’s granulo-
matosis does not respond sufficiently to cyclophosphamide and
glucocorticosteroids or suffers of intolerable side effects. Anec-
dotal data suggest that antithymocyte globulin (ATG) may be a
treatment option for these patients. We now describe 15 patients
treated with ATG for refractory Wegener’s granulomatosis.
Methods. Fifteen patients with histologically proven active
refractory Wegener’s granulomatosis (seven unresponsive to
cyclophosphamide, eight intolerant) were treated with ATG by
a protocol (SOLUTION protocol) designed by the European
Vasculitis Study (EUVAS) Group.
Results. Before ATG administration, patients had received
a mean of 5.2 (range 2 to 7) different therapeutic approaches
including glucocorticosteroids and cyclophosphamide in all and
experimental therapies in six, without control of disease activ-
ity [2.8 (range 1 to 7) relapses during a disease duration of 63.2
(range 18 to 180) months]. Thirteen of 15 patients showed a
favorable response to ATG with partial (N = 9) or complete
(N = 4) remission. During a follow-up of 21.8 (range 6 to 68)
months, seven patients relapsed after a mean of 8.4 (range 2 to
24) months (five minor and two major relapses). Six patients
are free of relapse for 22.3 (range 7 to 64) months. Two patients
died, 1 and 3 days following the first dose of ATG, due to pul-
monary hemorrhage and infection (one each). Although further
immunosuppressive treatment was required in all surviving pa-
tients, a less intensive regimen could be applied in 12. Beside
fever and chills associated with the first gift of ATG, ATG was
well tolerated, with infections being observed in five cases and
serum sickness in two.
Conclusion. Anti-T-cell–directed treatment with ATG may
be a therapeutic option for severe refractory Wegener’s granu-
lomatosis if simultaneous infections and fluid overload have
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been ruled out. In patients with alveolar hemorrhage, ATG
should only be used under special caution.
Wegener’s granulomatosis, the most common systemic
vasculitis associated with antineutrophil cytoplasmic an-
tibodies (ANCA), commonly takes a lethal course or
results in severe organ damage if left untreated. About
90% of cases respond to daily oral cyclophosphamide and
glucocorticosteroids, at the cost of substantial treatment-
induced morbidity. Relapses are experienced in at least
50% of cases [1–3]. The usual therapeutic management
of such cases is prolonged or readministration of cy-
clophosphamide. In frequent relapsers this often results
in high cumulative doses. Severe side-effects of cy-
clophosphamide such as malignancies and bone-marrow
toxicity were seen in 42% of patients in an important
follow-up study [2]. The greatest challenges in the man-
agement of Wegener’s granulomatosis are the mainte-
nance of remission, the avoidance of treatment related
morbidity, and the care of refractory cases who do not tol-
erate or respond to standard therapy. In the latter, there
is a definite need to replace cyclophosphamide by other
immunsuppressive drugs.
There is increasing evidence for a pathogenetic role of
T cells in Wegener’s granulomatosis (reviewed in [4, 5]),
including the finding of T cells in active vasculitic lesions
[6–11], the proliferation of T-helper cells from patients
with Wegener’s granulomatosis on stimulation with pro-
teinase 3 (PR3) [12–14], an overproduction of interferon-
c (INF-c) and tumor necrosis factor-a (TNF-a)
by T cells from Wegener’s granulomatosis patients [15],
and the correlation of soluble markers of T-cell acti-
vation with disease activity [16, 17]. Thus, there is suf-
ficient evidence for a pathogenetic role of T cells in
Wegener’s granulomatosis to justify anti-T-cell–directed
experimental therapeutic designs in refractory patients.
Initial reports have favored a beneficial effect of a treat-
ment using humanized antibodies against lymphocyte
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antigens such anti-CD4 and anti-CD52 [18, 19]. Ad-
ministration of antithymocyte globulin (ATG), a poly-
clonal preparation of antibodies directed against surface
antigens of activated lymphocytes, results in profound
lymphocyte depletion of rapid onset and thereby mod-
ifies (auto-) immunologically triggered inflammation
[20]. Mechanisms of action of ATG include classic
complement-mediated lysis of lymphocytes, clearance of
lymphocytes due to reticuloendothelial uptake, masking
of T-cell antigens, or expansion of negative regulatory
cells [21].
ATG, an established agent for the treatment of allo-
graft rejection [22], has been successfully administered to
patients with autoimmune disorders such as systemic scle-
rosis, systemic lupus erythematosus (SLE), autoimmune
hemolytic anemia, and rheumatoid arthritis [23–26].
In 1995, a favorable response was observed in four of
five patients with refractory Wegener’s granulomatosis
[27]. Encouraged by these results, the European Vasculi-
tis Study Group (EUVAS Group) prospectively studied
ATG in an open, multicenter protocol (SOLUTION pro-
tocol) to investigate the efficacy of ATG in Wegener’s
granulomatosis patients refractory to standard treatment.
METHODS
Patients
Within an open, prospective, uncontrolled protocol,
patients with refractory Wegener’s granulomatosis were
treated with ATG in nine academic centers of five
European countries. Patients gave written informed con-
sent before the inclusion. Ethical approval was obtained
in each participating center. Ten patients were enrolled
in the study from February 1997 to October 2001. Fur-
thermore, five patients were treated with ATG on com-
passionate use, but according to the protocol. Thus, 15
patients were used for safety and efficacy analysis. Un-
fortunately, no data are available on the number of pa-
tients who were considered for ATG treatment but did
not receive the drug. Although the protocol was open
also for patients suffering of microscopic polyangiitis
(MPA), no MPA patients were included. Wegener’s gran-
ulomatosis was histologically proven in all patients, and
all were cANCA/PR3-ANCA positive. Eight were male
and seven were female, with a mean age of 50.7 (range 36
to 65) years.
Disease extent
Diseae extent was assessed at entry, at 2 weeks, at 1,
3, 6, 9, 12 months, and then every 6 months, or at re-
lapse using the disease extent index (DEI) as published
previously [28]. Organ manifestations were recorded
as follows: E, upper respiratory tract; L, lung; K, kid-
ney; Ey, eye; H, cardiac involvement; S, skin; C, cen-
tral nervous system, P, peripheral nervous system; A,
arthritis/arthralgias and myalgias; GI, gastrointestinal
manifestation (each organ was worth 2 points), and B,
constitutional symptoms (fever >38◦C, undesired weight
loss >10% of body weight within less than 6 months)
(worth 1 point). The maximum possible score was 21
points.
All patients suffered of a generalized, severe course of
Wegener’s granulomatosis with a cumulative DEI of 8.7
(range 3 to 12). During disease duration of 63.2 (range 18
to 180) months prior to the administration of ATG, the
patients had suffered an average of 2.8 (range 1 to 7) re-
lapses. Previous therapies consisted of 5.2 (range 2 to 7)
different therapeutic approaches (Table 1), that included
glucocorticosteroids and daily oral cyclophosphamide in
all. The mean cumulative dose of cyclophosphamide was
56.5 g (range 10 to 150 g). Five cases had been treated with
plasma exchange, six with experimental therapies [four
mycophenolate mofetil, three intravenous immunoglob-
ulins, two cyclosporine A, and two 15-deoxyspergualine
(DSG)], without long-lasting control of disease activity.
Refractory Wegener’s granulomatosis/MPA was de-
fined by consensus within the EUVAS group as
(1) progressive disease unresponsive to at least
six weeks of standard treatment (cyclophosphamide/
glucocorticosteroids) or progressive disease in patients
intolerant of standard treatment (progressive disease
may include persistently active disease or major relapse
threatening life or organ function); and (2) constant
grumbling disease in patients who relapse after reduction
or omission of cytotoxic agents.
Definition of remission
The activity of disease was evaluated according to clin-
ical, radiologic, and serologic data. Complete remission
was defined as the absence of pathologic findings in these
variables attributable to active vasculitis, regardless of
ANCA titers. The absence of clinical disease activity was
indicated by a DEI of zero. Partial remission was defined
as partial regression of disease activity. Response to ATG
therapy was defined as induction of partial or complete
remission for at least 1 month. As a delayed response
to ATG had been observed previously [27], any improve-
ment of disease extent within 3 months of ATG treatment
was regarded to be an effect of therapy (for example,
patients who changed status from partial to complete
remission).
Definition of relapse
Major relapse required the recurrence of active
disease threatening the function of major organs (for
example, glomerulonephritis, pulmonary infiltrates, or
granulomata) [29]. Minor relapse required the recurrence
of disease activity of less severity, such as active vasculitis
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in nonvital organs (for example, arthralgia or nasal crust-
ing), or involvement of vital organs without threatening
organ function (for example, pulmonary symptoms such
as cough or wheeze without radiologic changes) [29].
Treatment protocol
It was the hypothesis of the study that ATG is able
to induce remission of refractory active or grumbling
Wegener’s granulomatosis/MPA.
Inclusion criteria were biopsy proven, ANCA-
associated Wegener’s granulomatosis/MPA with a re-
fractory course as defined by the criteria given above.
Exclusion criteria included allergy against rabbit pro-
teins, previous treatment with antilymphocyte antibodies,
patient age under 18 or over 75 years, previous ma-
lignancies, uncontrolled infection, including any human
immunodeficiency virus (HIV) infection, inadequate
contraception in fertile women, pregnancy, refractory
congestive heart failure or fluid overload, or coexistence
of any other multisystem autoimmune disease.
End points. For patients with progressive disease, in-
duction of remission was the primary end point. Main-
tenance of remission, sparing of immunosuppressants,
and side effects of ATG were secondary end points. For
patients with constant grumbling disease, maintenance
of remission and dose reduction of immunosuppressants
was the primary end point. Side effects of ATG were the
secondary end points.
Administration of ATG. Cytotoxic agents, intra-
venous immunoglobulins, or plasma exchange had to be
discontinued before ATG-treatment. Intracutaneous or
conjunctival testing of ATG was performed prior to the
infusion to exclude a presensitization. Fourteen patients
initially received 2.5 mg/kg body weight of rabbit anti-
human ATG (Thymoglobulin) (IMTIX SangStat, Lyon,
France). The ATG was infused via a central venous line
or a large caliber vein over 4 hours. The first dose was
2.5 mg/kg body weight. During a 10-day regimen, fur-
ther doses were adjusted to daily lymphocyte counts. If
lymphocyte counts were <150/lL no ATG was given.
In case of a lymphocyte count >150/lL and <300/lL,
1.5 mg/kg ATG was infused. Patients with lymphocyte
counts ≥300/lL received 2.5 mg/kg ATG. One patient,
who was treated with ATG on a compassionate basis,
received ATG-Fresenius (Fresenius AG, Bad Homburg,
Germany). The scheme of treatment described in the
Results section. To prevent allergy, all patients received
100 mg methylprednisolone before the first adminis-
tration of ATG, and azathioprine (2 mg/kg) was given
throughout ATG-treatment to prevent serum sickness.
If pyrexia, and/or rigors occurred, the infusion rate was
decreased. When chills had passed (usually within 1 to
2 hours), the infusion was to be continued. After the
course of ATG, the further use of immunosuppres-
sive drugs followed clinical demands and local prac-
tice. Prophylaxis with cotrimoxazol and amphotericin-B
suspension was suggested by the protocol to pre-
vent Pneumocystis carinii and Candida infection, cy-
tomegalovirus (CMV) prophylaxis was also optional.
RESULTS
Indication of ATG
All 15 patients suffered of active, refractory gener-
alized Wegener’s granulomatosis at the time of ATG
administration. No patient with grumbling disease was
included because of the inability to stop or reduce cy-
totoxic treatment. Seven patients received ATG due to
progressive disease under cyclophosphamide. Eight pa-
tients were intolerant of cyclophosphamide (four devel-
oped hemorrhagic cystitis, four had marrow failure, one
had jaundice, and one had nausea) and had a relapse
of disease. At the time of ATG administration, the pa-
tients showed a mean DEI of 4.9 (range 2 to 8) with ma-
jor organ involvement threatening organ function in all
(Table 1). Noteworthy, 11 of the 15 patients had severe
pulmonary disease (five had suspected pulmonary gran-
ulomata, three had massive pulmonary infiltrates with
overt pulmonary hemorrhage in two, and three were
unspecified), and six suffered of progressive renal in-
volvement. Fourteen of 15 patients were already on glu-
cocorticosteroids when ATG was administered.
The 14 patients who were treated with ATG from
IMTIX SangStat (Thymoglobulin) received a mean of
2.2 (range 1 to 5) infusions of ATG with a mean total
dose of 300 mg (150 mg to 500 mg). The patient who was
treated with ATG-Fresenius received five infusions of a
total dose of 1050 mg.
Response to ATG
Thirteen of 15 patients showed a favorable response
with partial (N = 9) or complete (N = 4) remission of dis-
ease activity (Table 1), including two of three cases with
pulmonary infiltrates/hemorrhage. Following the ATG
administration, the mean DEI declined from 4.9 prior
to ATG to 1.8 (range 0 to 4). Remaining disease activ-
ity in the nine patients with partial remission was re-
stricted to residual lesions such as residual pulmonary
opacities, nasal crusting, or persisting proteinuria in the
absence of microhaematuria with a stable creatinine. In-
terestingly, lesions of (suspected) granulomatous nature
such as pulmonary opacities and nasal crusting seemed
less likely to disappear completely (complete resolution
in three of nine patients affected; 33%) as compared with
lesions thought to be of merely vasculitic origin such as
pulmonary infiltrates, episcleritis, and glomerulonephri-
tis (complete resolution in 17 of 21; 81%) (Table 2).
All patients who entered remission showed at least a
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Table 2. Response to antithymocyte globulin (ATG) treatment in
suspected granulomatous versus suspected vasculitic lesionsa
Granulomatous Vasculitic
lesionsb lesionsc
Partial Complete Partial Complete
response response response response
Organs involved number number number number
Ear, nose, and 4 1 — —
throat (ENT)
Lungs 2 2 1 1
Skin — — 2
Peripheral nerves — — — 4
Kidneys — — 3 2
Eys — — — 2
Joints — — — 2
Constitutional — — — 4
symptoms
Sum 6/9 (67%) 3/9 (33%) 4/21 (19%) 17/21 (81%)
aIn three patients, pulmonary findings could not be classified, among them a patient
who died 3 days after the first administration of ATG (patient 8).
bLesions were classified as granulomatous if granuloma formation was proven by
histology, or if it was suspected by the clinical appearance of the lesion (pulmonary
nodules or severe nasal crusting, orbital pseudotumor).
cLesions were classified as vasculitic if vasculitis was demonstrated by histology
(including crescentic glomerulonephritis) in the absence of granuloma formation
or giant cells, or if the vasculitic nature of the lesion was suspected by its clinical
appearance (transient pulmonary infiltrates, purpura of the skin, episcleritis, arthralgias,
mononeuritis multiplex, or constitutional symptoms).
partial response within the first month following treat-
ment. However, six patients further improved within the
following 2 months, and two of these patients changed
status from partial to complete remission.
However, the administration of ATG was associated
with fatal complications, as two patients died, both in the
setting of extended pulmonary and renal involvement.
Patient 8 (pulmonary renal syndrome) died due to un-
controlled pulmonary hemorrhage 3 days after the first
administration of ATG. The second death occurred due to
pulmonary failure and sepsis the day following the first
administration of ATG in a patient with extensive pul-
monary cavitation (patient 14). Here, autopsy demon-
strated that pulmonary disease was complicated by
bacterial infection that had not been recognized prior to
the administration of ATG (methicillin-resistant Staphy-
lococcus aureus plus Coliform bacteriae). No further
deaths occurred during a mean follow up of 21.8 (range
6 to 68) months.
Further immunosuppressive treatment, including glu-
cocorticosteroids, was required in all surviving patients.
However, the intensity of immunosuppression could be
reduced in 11 cases (Table 1). Ten patients were able to
reduce the dose of corticosteroids, from a mean dose of
48.5 mg/day (range 5 mg to 100 mg) prior to ATG admin-
istration to a mean dose of 12.75 mg/day (range 2.5 mg
to 25 mg). Noteworthy, only one of the seven patients
who were treated with cyclophosphamide directly before
ATG administration remained on this drug thereafter,
and the use of myelosuppressive agents was restricted
to three cases (one patient bolus cyclophosphamide, two
azathioprine). Currently, six of the 13 surviving patients
are free of relapse for a mean of 22.3 (range 7 to 64)
months.
Seven patients relapsed after a mean of 8.4 (2 to 24)
months. Compared with the mean DEI 5.6 (3 to 8) at the
time of ATG administration in these seven patients, the
subsequent relapses were of a minor extent (mean DEI
2.9) (range 2 to 4). Five of the relapses were classified as
minor (mean DEI 2.8) (bronchitis, arthralgias, purpura,
and episcleritis), and two as major relapses (mean DEI
3.0) involving the lungs in both patients (one with pul-
monary infiltrates and one with an increase in size of
pulmonary granulomata). The pulmonary granulomata
(patient 3) responded to the addition of etanercept, a
TNF-a blocker. The patient who developed pulmonary
infiltrates (patient 12) showed progressive disease despite
reinstitution of cyclophosphamide treatment and finally
responded to plasma exchange.
The likelihood of subsequent relapse was increased in
patients who were not treated with cyclophosphamide
directly before the ATG administration (relapse in six
of seven surviving patients) as compared to patients
who were on treatment regimens with cyclophosphamide
(subsequent relapse in one of six cases). The cumulative
dose of cyclophosphamide seemed to be lower in patients
who did relapse following ATG administration as com-
pared to those who did not (37.8 g versus 70.2 g), but the
difference was statistically not significant.
ANCA were positive in all patients directly be-
fore ATG treatment as detected by indirect fluores-
cence and/or PR3 enzyme-linked immunosorbent assay
(ELISA). Follow-up on ANCA titers was available on
nine surviving cases. Within 6 months, ANCA titers be-
came negative in four of nine, declined by more than
2 titer steps in two and remained unchanged in three
further cases. Notably, in one of the patients, ANCA
remained negative despite subsequent relapse after
6 months.
Side effects of ATG
Ten patients experienced fever and chills associated
with the first application of ATG. Further side effects
were restricted to a minority of cases: Two patients (pa-
tients 2 and 11) suffered from serum sickness, clinically
manifested with purpura, arthralgias, dyspnea, and fever.
Both cases quickly responded to plasma exchanges with-
out any additional immunosuppressive therapy. One of
the patients was tested for IgM rheumatoid factor and
showed a positive test.
Infections. Besides the patient who died of pulmonary
bacterial infection, five further episodes of severe infec-
tions were observed. Three weeks after ATG administra-
tion, one patient developed an abscess of a labium majus
(S. aureus) that required surgical drainage. Further infec-
tions (each in one case) included urinary tract infection,
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pneumonia (10 days after last dose of ATG, most likely of
bacterial origin, response to antibiotic treatment), CMV
infection, and Clostridium difficile colitis.
DISCUSSION
The present study shows that a 10-day regimen of ATG
induced remission in six of seven Wegener’s granulo-
matosis patients who showed progressive disease under
treatment with cyclophosphamide and in seven of eight
additional patients in whom cyclophosphamide had to
be avoided due to severe side effects. Importantly, the
effect of ATG may be long-lasting, as six patients are
still free of relapse for a mean of 22.3 (range 7 to 64)
months. But also in the seven patients who subsequently
relapsed, the disease extent at the time of relapse was lim-
ited in comparison to the disease extent directly before
ATG administration (mean DEI 2.9 vs. 5.6). Thus, ATG
may have contributed to a less aggressive course in these
refractory cases.
However, two fatalities occurred which was not unex-
pected due to the fact that all patients were very ill at
the time they received ATG. Patient 8, who died 3 days
after the first administration of ATG due to pulmonary
hemorrhage might have received the drug too late dur-
ing his fulminant course. It has been described previously
and also we observed here that response to ATG in some
patients may be delayed by an interval of several weeks
[27]. Autopsy of patient 14, who died the day following the
first administration of ATG, demonstrated uncontrolled
pulmonary infection as well as active vasculitic lesions.
This case has to be regarded as a protocol violation, as
uncontrolled infection was a contraindication for ATG
treatment. In large cohorts of Wegener’s granulomato-
sis patients, including cases with mild-to-severe disease,
deaths due to infections have been observed to occur
in 3% to 12% of cases during a mean follow-up of 7 to
12 years (reviewed in [2]). The relatively high death rate
reported here (two of 15 cases) must be interpreted in the
context of the most severe course of these patients with
an increased likelihood of infection.
Retrospectively, however, this case should not have
been treated with ATG, and it should be stressed that
infections must be actively excluded prior to the use of
ATG, in order to archive an optimal risk benefit ratio.
If it is not possible to sufficiently rule out simultaneous
infections, the use of ATG should be discouraged.
The present study confirms and extends an earlier
report, that demonstrated a positive response to rab-
bit ATG in four of five Wegener’s granulomatosis pa-
tients, with partial (N = 3) or complete (N = 1) remis-
sion of disease activity, during a follow-up of 5 months
to 51/2 years [27, 31]. This cohort was not included in
the current study. The patients were recruited on sim-
ilar grounds as in this study. All five cases suffered of
Table 3. Summarized experience with antithymocyte globulin (ATG)
in refractory antineutrophil cytoplasmic antibodies
(ANCA)-associated systemic vasculitis
Intensity
reduction of
Partial Complete immunosup-
Number remission remission pressants
Reference of cases Diagnosis number number number
[27] 5 all WG 4 none 4
[31], follow-up 1 WG — 1 yes
of [27]
[30] 1 MPA 1 — ?
EUVAS Group 15 all WG 9 4 12
SOLUTION
Abbreviations are: WG, Wegener’s granulomatosis; MPA, microscopic polyangiitis;
EUVAS, European Vasculitis Study Group.
active, severe refractory Wegener’s granulomatosis, had
been treated previously with cyclophosphamide and glu-
cocorticosteroids and received a similar regimen of ATG.
Interestingly, granulomatous lesions such as orbital pseu-
dotumors and nasal/sinus granulomata (improvement at
one of three sites of active disease) did not respond as well
as vascular lesions (episcleritis and glomerulonephritis;
improvement at five of five sites of active disease) [27]. A
similar trend was seen in the cohort presented here, with
a complete response to ATG of 81% of the vasculitis in
contrast to 33% of the granulomatous lesions (Table 2).
Although the numbers are too small to perform any
meaningful statistical tests, it may be speculated that
granulomatous lesions do not respond as good to ATG as
lesions of a purely vasculitic nature. This is in line with a
relative resistance of retro-orbital pseudotumors and sub-
glottic/bronchial stenosis observed under standard treat-
ment with cyclophosphamide and glucocorticosteroids
[1]. Extensive fibrotic changes in some of the lesions may
partially explain the problem [1]. It is well known that ac-
tive T cells can be demonstrated in granulomatous lesions
in Wegener’s granulomatosis [7, 9]. It has not been investi-
gated, to which extend these T-cell infiltrates persist after
treatment with ATG. Regression of active vasculitis has
also been documented in a case of pANCA associated
MPA (pulmonary and renal involvement, dialysis-
dependent), who was treated with ATG and glucocor-
ticosteroid pulses (clinical remission, off dialysis) [30]. A
PubMed search performed on May 25, 2003, using the
search terms “ATG” and “ANCA,” “vasculitis,” “angi-
itis,” and “arteritis” did not reveal any further reports
on cases of Wegener’s granulomatosis/MPA treated with
ATG. Table 3 summarizes the experience published on
ATG treatment of these disorders.
It is unclear at present whether patients with pul-
monary disease, especially cases with pulmonary hem-
orrhage, should be considered for ATG treatment. Nine
of the 11 patients described here with active pulmonary
disease responded to treatment. Among the responders
were two of three cases with suspected/overt alveolar
bleeding. But one of these three cases (a patient with
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massive alveolar hemorrhage) died of pulmonary failure
1 day after the first dose of ATG. Because the administra-
tion of ATG may lead to pulmonary infiltrates [32], acute
respiratory distress syndrome [33], and to pulmonary
edema [34], the risk of ATG must be balanced against
the possible benefits in patients with serious pulmonary
problems, and alternative options should be considered.
Especially, fluid overload should be treated accordingly
before the administration of ATG. The experience gained
from the three patients presented here is too limited to
give any other meaningful recommendations, and pre-
vious case series of Wegener’s granulomatosis patients
treated with ATG did not include patients with alveolar
hemorrhage [27]. However, a good response to ATG has
been described in a case of pulmonary renal syndrome
due to MPA, without pulmonary complications follow-
ing the administration of ATG [30]. Because pulmonary
infiltrates may be caused both by alveolar bleeding and
by lung infections, special care must be taken to exclude
underlying pulmonary infections in these patients before
ATG is administered.
In the patients reported previously [27, 30], glucocor-
ticosteroid doses could be reduced in all four respon-
ders, and all except two patients were free of other
immunosuppressive agents for up to 31/2 years. Although
long-term remissions of up to 51/2 years were also ob-
served in the present study, all patients published now are
on continued immuosuppressive therapy. Furthermore,
all patients still receive glucocorticosteroids, but a dose-
sparing effect was observed in ten of 13 cases. It could
be argued that concomitant treatment with glucocorto-
costeroids added significantly to the favorable response
of ATG. However, it is known that glucocortocosteroids
alone are not capable to induce or maintain remission in
Wegener’s granulomatosis [1]. Also, 14 of the 15 patients
received glucocorticosteroids before the administration
of ATG, without control of disease activity.
T cells and Wegener’s granulomatosis
The clinical response to ATG favors a pathogenetic
role of T cells in Wegener’s granulomatosis and supports
existing evidence of a dysregulated cellular immunity in
this disorder, although the participation of antigen spe-
cific T cells in the pathogenesis of Wegener’s granulo-
matosis at initiation and effector stages of the immune
response has not been formally proven. Although not
universally accepted [15], there is some evidence from
in vitro studies that T-helper cells and peripheral blood
mononuclear cells from Wegener’s granulomatosis pa-
tients proliferate on stimulation with PR3 [12–14], but
no specific PR3 sequence could be identified that was
preferentially recognized [35]. However, effectors of cell-
mediated immunity such as CD4+ and CD45 RO-positive
T cells have been demonstrated in active vasculitic lesions
in lung and nasal biopsies as well as in glomeruli affected
by pauci-immune crescentic glomerulonephritis [6, 7, 10,
36]. An abundance of CD28− T cells was found in gran-
ulomatous lesions of the respiratory tract and in bron-
choalveolar lavage fluid from Wegener’s granulomatosis
patients [11]. Although there are conflicting data on T-
helper cell 1/T-helper cell 2 dominance [6, 8, 9, 15], a
polarization toward T-helper cell 1 immune response is
favored by most authors and was recently shown to be
reversible by immunosuppressive treatment [36].
Peripheral CD4+ T cells of patients with Wegener’s
granulomatosis were shown to exhibit increased prolif-
erative responses and to overproduce IFN-c and TNF-a,
which might be of significance for the generation of the
granulomatous lesions via their effects on cellular recruit-
ment [15]. Production of these cytokines has also been
demonstrated by CD4+ CD28− T cells within granulo-
matous lesions of Wegener’s granulomatosis patients [9].
Elevated levels of T-cell activation markers such as solu-
ble interleukin 2 (IL-2) receptor and soluble CD30 were
shown to correlate with the clinical activity of Wegener’s
granulomatosis and remain elevated during periods of
complete remission [16, 17]. In animal models of crescen-
tic (although not ANCA-associated) glomerulonephritis
(summarized by Tipping et al [37]), evidence of a pivotal
role of cell-mediated immunity continues to accumulate.
This includes the requirement of CD4+ cells (dominance
of T-helper cell1 immune response), but not B cells for
the induction of disease [37, 38], with no IgG binding to
glomerular basement membrane (GBM) or C3 deposi-
tion being detected in a recent model [39]. Therapy with
anti-CD8 monoclonal antibody was shown to be effective
in the prevention and treatment of the disease [40].
A pathogenetic role of lymphocytes in crescentic pauci-
immune glomerulonephritis is further substantiated by
a randomized trial that demonstrated a similar efficacy
of lymphocyte apheresis as compared with pulse gluco-
corticosteroids [41]. DSG, which is thought to selectively
inhibit cell-mediated immunity [42], was also shown to
induce remission in 14 of 20 patients with refractory We-
gener’s granulomatosis and MPA [43]. Anisperimus (LF
15-0195), a substance closely related to DSG, may be of
similar efficacy (induction of remission in seven of nine
cases of refractory systemic vasculitis) [abstract; The Lab-
oratories Fournier LF 15-0195 Vasculitis Study Group,
Cleve Clin J Med 69 (Suppl 2):SII 191, 2002]. The good
response of refractory Wegener’s granulomatosis to ATG
reported here also favors the development of less toxic
therapeutic concepts that selectively suppress the cell-
mediated immune response. These concepts are urgently
awaited to overcome the era of cyclophosphamide and
high dose glucocorticosteroids [44].
Finally, the depletion of autoreactive T cells by ATG
may also affect B-cell function, as indicated by the ob-
servation that ANCA titers declined or became negative
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in the majority of cases described here and in an ear-
lier study [27]. Because ANCA by themselves also seem
to be of pathogenetic significance in Wegener’s granulo-
matosis, this may have also influenced the outcome. Pos-
sibly, the relative roles of cell-mediated immunity and
antibody-mediated effects may relate to the phase of dis-
ease. The pathogenetic role of the humoral immune re-
sponse is further substantiated by a recent report on the
induction of crescentic glomerulonephritis and vasculitis
by passive infusion of mouse antimyeloperoxidase IgG
into both immune-deficient and immune-competent mice
[45]. Correspondingly, an excellent response of refrac-
tory Wegener’s granulomatosis was observed following
the administration of a monoclonal anti-CD20 antibody
(rituximab) [46], and plasma exchange, which has been
tested in a large EUVAS trial in severe renal Wegener’s
granulomatosis/MPA, appears to be superior to glucocor-
ticosteroid boli in this setting [abstract; Gaskin G, et al,
J Am Soc Nephrol 13:F-FC110, 2002]. Furthermore, on a
more downstream level compared to ATG, anti-TNF-a
treatment has been used successfully to treat refractory
Wegener’s granulomatosis [47].
Side effects
Beside fever and chills experienced by most patients,
side effects were restricted to a minority of cases: serum
sickness, previously observed in two of five Wegener’s
granulomatosis patients [27] and in about 10% of re-
nal transplant patients [22], was now seen in two cases
and rapidly improved after institution of plasma ex-
change. IgM rheumatoid factor, demonstrated in the pa-
tient tested here, may have contributed to this reaction,
as it may cross react with rabbit IgG and is frequently
present in active Wegener’s granulomatosis [1]. Whether
azathioprine, which the patients received during ATG
treatment in order to prevent serum sickness, had any
positive effect remains speculative.
CMV infection occurred in only one case, but is fre-
quently associated with ATG treatment after allograft
transplantation and may show an aggravated course.
Further infectious complications of the present cohort
responded to treatment and did not lead to permanent
morbidity.
Special care is necessary to protect the patients from
infections, and the use of prophylactic treatment against
bacterial, fungal, and viral infections such as CMV should
be recommended. Follow-up studies after kidney trans-
plantation demonstrate that ATG increases the risk for
malignant disorders [48], but no malignancies were ob-
served here during a mean follow-up of 21.8 months.
CONCLUSION
Using a standardized regimen of ATG in patients with
active, refractory Wegener’s granulomatosis, we were
able to induce remission in 13 of 15 cases. None of the
patients was able to quit immunsuppressive therapy, but
the intensity of immunosuppression could be reduced in
12. With few exceptions, ATG treatment was well toler-
ated. The response to ATG supports the concept that T
cells play a pathogenetic role in ANCA-associated sys-
temic vasculitis.
Outside controlled randomized trials, which are un-
likely to be performed due to the rarity of the
condition, patients suffering of refractory Wegener’s
granulomatosis should be managed with individualized
treatment schemes. Although the present study was open
and uncontrolled, ATG seems to be a promising treat-
ment option for these severely ill patients. However, in
order to avoid fatal side effects, ATG should only be ad-
ministrated if simulatenous infections and fluid overload
have been ruled out or treated sufficiently. In patients
with alveolar hemorrhage, who are known to be espe-
cially prone to infections, alternative options for treat-
ment should be considered.
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